Technical Articles

As an important member of the RAS family, KRAS gene mutations have a high incidence and clinical relevance in human malignant tumors, and have become one of the core concerns in the field of cancer research.

Mutations in the KRAS gene represent a significant challenge in cancer treatment, particularly in pancreatic cancer, colorectal cancer, and non-small cell lung cancer (NSCLC). These mutations result in the constitutive activation of the KRAS protein, leading to hyperactivation of downstream signaling pathways and promoting tumor cell growth. However, the lack of binding pockets on the KRAS protein surface has made it difficult for traditional small-molecule drugs to directly target KRAS, rendering it once deemed an "undruggable" target.

The KRAS protein is an important target protein in cancer. The KRAS gene, whose full name is Kirsten rat sarcoma viral oncogene homolog, is translated as "Kirsten rat sarcoma virus oncogene homolog". The protein encoded by the KRAS gene is a small GTPase, which belongs to the RAS superfamily of proteins.